

# Analyst Report

[Français – English]

Galina Sotnikova-Anquez  
Jean-Pierre Loza, PhD



## Intrasense

Euronext Growth Paris : ALINS [FR0011179886]

23/05/2018

**Estimated Share Price : € 1,01**

Estimated Market Cap. (€M)*	15,04	YTD High/Low (€)	0.89/0,45
Share price (€)*	0,45	3-month average daily vol.	827 250
Market Cap. (€M)*	6,7	Free Float	2%
Number of shares (M)	14.9	Estimated Net Cash (€M)	0,7
Eligibility to PEA	YES	Closing date of the accounts	12/31/18

\* as of 23/05/2018

### A complete offer for medical imaging

**Intrasense announces that it enters into exclusive negotiations with DMS Group. Our team maintains the target price at € 1.01 per share.**

#### Project of contribution of the activities of DMS Imaging, division of DMS Group, to Intrasense

Intrasense and DMS Group, high-tech imaging specialists at the service of medical diagnostics, are launching a strategic project to develop a new and complete offer.

DMS Imaging, the imaging division of DMS Group, is today the French leader in the development, design and manufacture of imaging systems dedicated to radiology, bone densitometry, 3D modeling and posturology.

Intrasense and DMS Group, which are targeting

### Une offre complète pour l'imagerie médicale

**Intrasense annonce entrer en négociation exclusive avec DMS Group. Notre équipe maintient l'objectif du cours à € 1,01 par action.**

#### Le projet d'apport des activités de DMS Imaging, division de DMS Groupe, à Intrasense

Intrasense et DMS Group, spécialistes de l'imagerie de haute technologie au service du diagnostic médical, lancent un projet stratégique en vue d'allier leurs savoir-faire complémentaires pour proposer une offre complète.

DMS Imaging, la division imagerie de DMS Group, se positionne aujourd'hui comme le leader français du développement, de la conception et la fabrication de systèmes d'imagerie dédiés à la radiologie, à l'ostéodensitométrie, la modélisation 3D et la posturologie.

the same global market, have decided to combine their complementary expertise in the field of advanced medical imaging to develop new offers to the market.

Both companies organize this merger strategy to create a differentiating and high value-added offer. DMS Group plans to associate its technological base in radiology tables together with Intracense software applications.

For Intracense this operation opens excellent perspectives of market access and corresponds to its new promising strategy, consisting of focusing on the industry.

### Details of the operation

The transaction aims to consolidate the imaging activities of the two companies within Intracense, through the contribution by DMS Group of the activities of its medical imaging division, DMS Imaging.

DMS Group would become the majority shareholder of Intracense and pursue its diversification strategy, which has been engaged since 2014 through the development of its DMS Wellness and DMS Biotech divisions.

Intracense, beyond becoming the medical imaging division of DMS Group, will continue to intensify its commercial developments and the execution of its strategy initiated in 2017.

The proposed partial contribution of assets induces a valuation of the contributions equal to 5.7 times the valuation of the Intracense group based on provisional valuations (still to be validated by the two companies) estimated at 40 M € for the Medical Imaging division of DMS Group and € 7 million (on a fully diluted basis) for Intracense.

The listing of Intracense shares on the Euronext Growth market would be maintained, as well as the listing of DMS Group shares, on the regulated market of Euronext Paris (Compartment C).

The definitive parity proposed for the

Intracense et DMS Group qui adressent le même marché mondial, ont décidé d'unir leurs expertises, complémentaires dans le domaine de l'imagerie médicale de pointe, afin de proposer une offre complète au marché.

Les deux sociétés envisagent un rapprochement en vue de constituer une offre à forte valeur ajoutée. DMS Group souhaite ainsi associer les applicatifs logiciels d'Intracense à la technologie de ses tables de radiologie.

Pour Intracense, cette opération élargit fortement son accès au marché et s'inscrit parfaitement dans sa nouvelle stratégie prometteuse, consistant à se concentrer sur la vente aux industriels.

### Détails de l'opération

L'opération vise au regroupement des activités d'imagerie des deux sociétés au sein d'Intracense, à travers l'apport par DMS Group des activités de sa division d'imagerie médicale, DMS Imaging.

DMS Group deviendrait l'actionnaire majoritaire d'Intracense et poursuivrait sa stratégie de diversification engagée depuis 2014 à travers le développement de ses divisions DMS Wellness et DMS Biotech.

Intracense, tout en devenant le pôle imagerie médicale de DMS Group, poursuivrait l'intensification de ses développements commerciaux et l'exécution de sa stratégie initiée en 2017.

L'apport partiel d'actifs proposé induit une valorisation des apports égale à 5,7 fois la valorisation du groupe Intracense sur la base de valorisations provisoires (devant encore faire l'objet de validations par les deux sociétés) estimées à 40 M€ pour le pôle Imagerie Médicale de DMS Group et de 7 M€ (sur une base entièrement diluée) pour Intracense.

La cotation des actions Intracense sur le marché Euronext Growth serait maintenue, ainsi que la cotation des actions DMS Group, sur le marché réglementé d'Euronext Paris (Compartment C).

La parité définitive proposée pour l'apport fera

contribution will be the object of a press release as soon as the finalization of the valuation of the assets.

The Boards of Directors of Intrasure and DMS Group are expected to meet again by June 2018 to finalize the terms of the contribution, authorize the signing of the asset contribution agreement and convene the general meetings of the shareholders of Intrasure and DMS Group.

## Valuation

The strategy put in place by Intrasure management, focused on key accounts, highlighting innovation via Myrian® Studio and Myrian® Imaging Layer, and on more industrial partnerships, will be strengthened by cooperation with DMS Group and will express itself in 2018. Aurgalys Value team maintains the target price at € 1.01 per share.

l'objet d'un communiqué de presse dès la finalisation des travaux de valorisation des actifs.

Les Conseils d'administration d'Intrasure et de DMS Group devraient se réunir à nouveau d'ici juin 2018 afin d'arrêter les modalités définitives de l'apport, d'autoriser la signature du traité d'apport et de convoquer les assemblées générales des actionnaires d'Intrasure et de DMS Group.

## Valorisation

La stratégie mise en place par le management d'Intrasure, avec un focus sur les grands comptes, la mise en avant des innovations produits Myrian® Studio et Myrian® Imaging Layer, et le renforcement des partenariats industriels, sera confortée par le projet de rapprochement avec DMS Group et s'exprimera en 2018. Notre équipe maintient l'objectif de cours à € 1,01 par action.

### Euronext since/ depuis May 23th, 2017

---


<i>Intrasure</i>	<i>-23%</i>
<i>Next Biotech</i>	<i>+24%</i>
<i>CAC Healthcare</i>	<i>-13%</i>
<i>CAC 40</i>	<i>+4%</i>
<i>CAC Small</i>	<i>+7%</i>

---

*\*Index of French smallcaps (less than €1B market capitalization at time of inclusion) in the healthcare and life sciences sector, listed on Euronext Paris  
See <http://www.aurgalys.com/aurgalys-indices>*

## Intrasense one-year stock performance, by comparison with Alys France Index, as of May 23th, 2018

Performance à un an d'Intrasense en comparaison avec l'indice Alys France, au 23 mai 2018



## Financial

<b>EARNINGS PER SHARE (€)</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018e</b>	<b>2019e</b>	<b>2020e</b>
EPS	-0,44	-0,14	-0,16	-0,01	0,06	0,09
<b>Income Statement (€M)</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018e</b>	<b>2019e</b>	<b>2020e</b>
Revenue	2,9	3,0	2,2	4,2	5,4	6,0
EBIT	-2,2	-1,9	-2,3	-0,5	0,4	0,7
<b>Net Income</b>	<b>-2,8</b>	<b>-1,8</b>	<b>-2,1</b>	<b>-0,1</b>	<b>0,8</b>	<b>1,1</b>
<b>BALANCE SHEET (€M)</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018e</b>	<b>2019e</b>	<b>2020e</b>
Non Current Assets	1,5	1,3	1,4	1,7	2,0	2,1
Current Assets	4,7	4,0	2,3	2,7	3,0	3,8
<i>Including cash &amp; cash equivalent</i>	<i>1,2</i>	<i>0,7</i>	<i>0,6</i>	<i>0,6</i>	<i>0,9</i>	<i>1,6</i>
<b>Total Assets</b>	<b>6,2</b>	<b>5,3</b>	<b>3,7</b>	<b>4,4</b>	<b>5,0</b>	<b>5,9</b>
<b>LIABILITIES AND SHAREHOLDER'S EQUITY</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018e</b>	<b>2019e</b>	<b>2020</b>
<b>Total Equity</b>	<b>1,2</b>	<b>1,8</b>	<b>0,6</b>	<b>0,8</b>	<b>1,6</b>	<b>2,7</b>
Financial Debt	3,0	1,5	1,7	2,4	2,1	1,9
Other Debt	1,9	2,0	1,3	1,3	1,3	1,4
<b>Total Liabilities and Shareholder's equity</b>	<b>6,2</b>	<b>5,3</b>	<b>3,7</b>	<b>4,4</b>	<b>5,0</b>	<b>5,9</b>
<b>CASH FLOW STATEMENT (€M)</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018e</b>	<b>2019e</b>	<b>2020e</b>
Cash flow from operating activities	-0,4	-0,7	-0,7	0,7	1,4	2,1
Cash flow from investment activities	-1,3	-0,8	-0,9	-0,9	-1,0	-1,0
Cash flow from financing activities	1,9	1,8	0,8	0,3	-0,2	-0,4
<b>Net change in Cash</b>	<b>0,2</b>	<b>0,3</b>	<b>-0,8</b>	<b>0,1</b>	<b>0,3</b>	<b>0,7</b>

## Disclaimer

This study has been prepared based on general and public information assumed to be complete, exact and pertinent. Although all necessary precautions have been taken to assure that the information used originates from reliable sources, Aurgalys does not guarantee the accuracy or completeness of this report. Neither Aurgalys nor any of its associates may be held liable in any manner whatsoever in the event that any of the documents and other information on which the study has been based proves to be inaccurate and in any way resulting in the possible misrepresentation of the economic and financial position of the Company or any other relevant information. The valuation contained herein has been prepared in accordance with the best assessment of Aurgalys as at the date of preparation of this study and has been based on the information as described above. Neither Aurgalys nor its associates guarantee that the value so obtained will correspond or coincide with the price that could effectively be paid in a transaction or established in a negotiation or any transaction or calculation involving the Company. This document does not constitute an offer or an invitation to buy or subscribe to negotiable or other securities. It may not be used in any manner in support of or in connection with any contract or commitment. This document is being supplied for information purposes only and may not be reproduced or passed on to any third party without the written authorization of Aurgalys. This document has been provided to the Company prior to its distribution. Aurgalys does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. You may call +33(0)1 75 66 20 53 or write to [g.sotnikova@aurgalys.com](mailto:g.sotnikova@aurgalys.com) to request a copy of this independent research

## About Aurgalys

First company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext).

### Aurgalys

1, rue Pierre Fontaine, 91058 Evry Cedex,  
France  
[www.aurgalys.com](http://www.aurgalys.com)

### Join us on

[Linkedin](#)

### Follow us on

Twitter [@aurgalys](#)